Literature DB >> 21756903

Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability.

Yi-Song Chen1, Suh-Ciuan Lim, Mei-Hsuan Chen, Roy A Quinlan, Ming-Der Perng.   

Abstract

Alexander disease is a primary genetic disorder of astrocyte caused by dominant mutations in the astrocyte-specific intermediate filament glial fibrillary acidic protein (GFAP). While most of the disease-causing mutations described to date have been found in the conserved α-helical rod domain, some mutations are found in the C-terminal non-α-helical tail domain. Here, we compare five different mutations (N386I, S393I, S398F, S398Y and D417M14X) located in the C-terminal domain of GFAP on filament assembly properties in vitro and in transiently transfected cultured cells. All the mutations disrupted in vitro filament assembly. The mutations also affected the solubility and promoted filament aggregation of GFAP in transiently transfected MCF7, SW13 and U343MG cells. This correlated with the activation of the p38 stress-activated protein kinase and an increased association with the small heat shock protein (sHSP) chaperone, αB-crystallin. Of the mutants studied, D417M14X GFAP caused the most significant effects both upon filament assembly in vitro and in transiently transfected cells. This mutant also caused extensive filament aggregation coinciding with the sequestration of αB-crystallin and HSP27 as well as inhibition of the proteosome and activation of p38 kinase. Associated with these changes were an activation of caspase 3 and a significant decrease in astrocyte viability. We conclude that some mutations in the C-terminus of GFAP correlate with caspase 3 cleavage and the loss of cell viability, suggesting that these could be contributory factors in the development of Alexander disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756903      PMCID: PMC4308095          DOI: 10.1016/j.yexcr.2011.06.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  70 in total

1.  Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies.

Authors:  Harald Bär; Bertrand Goudeau; Sarah Wälde; Monique Casteras-Simon; Norbert Mücke; Alexey Shatunov; Y Paul Goldberg; Charles Clarke; Janice L Holton; Bruno Eymard; Hugo A Katus; Michel Fardeau; Lev Goldfarb; Patrick Vicart; Harald Herrmann
Journal:  Hum Mutat       Date:  2007-04       Impact factor: 4.878

2.  Identification and characterization of GFAPkappa, a novel glial fibrillary acidic protein isoform.

Authors:  Jenny Blechingberg; Ida Elisabeth Holm; Karsten Bork Nielsen; Torben Heick Jensen; Arne Lund Jørgensen; Anders Lade Nielsen
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

Review 3.  Towards a molecular description of intermediate filament structure and assembly.

Authors:  David A D Parry; Sergei V Strelkov; Peter Burkhard; Ueli Aebi; Harald Herrmann
Journal:  Exp Cell Res       Date:  2007-04-12       Impact factor: 3.905

Review 4.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

5.  Early mitochondrial dysfunction in an infant with Alexander disease.

Authors:  Cristina Cáceres-Marzal; Julián Vaquerizo; Enrique Galán; Santiago Fernández
Journal:  Pediatr Neurol       Date:  2006-10       Impact factor: 3.372

6.  Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.

Authors:  Guomei Tang; Zhiheng Xu; James E Goldman
Journal:  J Biol Chem       Date:  2006-10-10       Impact factor: 5.157

7.  Caspase-3 activation in astrocytes following postnatal excitotoxic damage correlates with cytoskeletal remodeling but not with cell death or proliferation.

Authors:  Laia Acarin; Sonia Villapol; Maryam Faiz; Troy T Rohn; Bernardo Castellano; Berta González
Journal:  Glia       Date:  2007-07       Impact factor: 7.452

Review 8.  Alexander disease: putative mechanisms of an astrocytic encephalopathy.

Authors:  C Mignot; O Boespflug-Tanguy; A Gelot; A Dautigny; D Pham-Dinh; D Rodriguez
Journal:  Cell Mol Life Sci       Date:  2004-02       Impact factor: 9.261

9.  Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin.

Authors:  Toru Nakazawa; Masumi Takeda; Geoffrey P Lewis; Kin-Sang Cho; Jianwei Jiao; Ulrika Wilhelmsson; Steven K Fisher; Milos Pekny; Dong F Chen; Joan W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

10.  Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.

Authors:  Shalina S Ousman; Beren H Tomooka; Johannes M van Noort; Eric F Wawrousek; Kevin C O'Connor; David A Hafler; Raymond A Sobel; William H Robinson; Lawrence Steinman
Journal:  Nature       Date:  2007-06-13       Impact factor: 49.962

View more
  19 in total

1.  Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.

Authors:  Tai-Seung Nam; Jin Hee Kim; Chi-Hsuan Chang; Woong Yoon; Yoon Seok Jung; Sa-Yoon Kang; Boo Ahn Shin; Ming-Der Perng; Seok-Yong Choi; Myeong-Kyu Kim
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

2.  Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease.

Authors:  Michael R Heaven; Landon Wilson; Stephen Barnes; Michael Brenner
Journal:  J Biol Chem       Date:  2019-09-04       Impact factor: 5.157

Review 3.  Review on intermediate filaments of the nervous system and their pathological alterations.

Authors:  Claire Lépinoux-Chambaud; Joël Eyer
Journal:  Histochem Cell Biol       Date:  2013-06-08       Impact factor: 4.304

Review 4.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

5.  Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.

Authors:  Laura R Moody; Gregory A Barrett-Wilt; Michael R Sussman; Albee Messing
Journal:  J Biol Chem       Date:  2017-02-21       Impact factor: 5.157

6.  Alexander disease.

Authors:  Albee Messing; Michael Brenner; Mel B Feany; Maiken Nedergaard; James E Goldman
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

Review 7.  Alexander disease: models, mechanisms, and medicine.

Authors:  Tracy L Hagemann
Journal:  Curr Opin Neurobiol       Date:  2021-11-23       Impact factor: 6.627

8.  Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.

Authors:  Tracy L Hagemann; Berit Powers; Ni-Hsuan Lin; Ahmed F Mohamed; Katerina L Dague; Seth C Hannah; Gemma Bachmann; Curt Mazur; Frank Rigo; Abby L Olsen; Mel B Feany; Ming-Der Perng; Robert F Berman; Albee Messing
Journal:  Sci Transl Med       Date:  2021-11-17       Impact factor: 17.956

9.  A report of two cases of bulbospinal form Alexander disease and preliminary exploration of the disease.

Authors:  Xiaoxuan Song; Jingwen Jiang; Wotu Tian; Feixia Zhan; Zeyu Zhu; Binyin Li; Huidong Tang; Li Cao
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

10.  Will posttranslational modifications of brain proteins provide novel serological markers for dementias?

Authors:  Y Wang; M G Sørensen; Q Zheng; C Zhang; M A Karsdal; K Henriksen
Journal:  Int J Alzheimers Dis       Date:  2012-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.